New-generation vaccines against cholera
نویسندگان
چکیده
منابع مشابه
Oral vaccines against cholera.
The current seventh pandemic of cholera, caused by serogroup O1, El Tor biotype, has now involved almost the entire developing world. The ongoing dynamic epidemiology of cholera, involving evolution of new strains, prolonged and more frequent epidemics, increased antimicrobial resistance, and awareness of the role of climate change upon the global burden has returned cholera to the forefront of...
متن کاملStatus of New Cholera Vaccines
The prospect of developing an effective cholera vaccine has improved in recent years, with increased understanding of the mucosal immune system that protects against enteric infections and the discovery that volunteers recovering from cholera were substantially protected against reinfection for several years. The ideal vaccine would be cheap, safe, easy to administer, and effective after a sing...
متن کاملPolicymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia.
Face-to-face interviews and meetings with more than 160 policymakers and other influential professionals in seven large Asian countries (Bangladesh, China, India, Indonesia, Pakistan, Thailand and Vietnam) were conducted to survey opinions regarding the need for, and potential uses of new-generation vaccines against cholera, typhoid fever and shigellosis. Despite several barriers to their uptak...
متن کاملComparing New-Generation Candidate Vaccines against Human Orthopoxvirus Infections
The lack of immunity to the variola virus in the population, increasingly more frequent cases of human orthopoxvirus infection, and increased risk of the use of the variola virus (VARV) as a bioterrorism agent call for the development of modern, safe vaccines against orthopoxvirus infections. We previously developed a polyvalent DNA vaccine based on five VARV antigens and an attenuated variant ...
متن کاملCholera vaccines.
Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is available. Outside the United States, 2 ad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Gastroenterology & Hepatology
سال: 2011
ISSN: 1759-5045,1759-5053
DOI: 10.1038/nrgastro.2011.174